EULAR recommends methotrexate (MTX), combined with short-term glucocorticoids as first-line treatment for early Rheumatoid arthritis (RA). In the CareRA trial, the COBRA-Slim regimen (MTX 15 mg/d) provided the best balance between efficacy, safety and cost-effectiveness. The CareRA2020 trial was funded by the Belgian Health Care Knowledge Centre (KCE) Trials Program, a national public funding program of non-commercial trials. The CareRA2020 trial included 276 patients, of which 155 (56%) were classified as sufficient and 121 (44%) as insufficient responders. Of the insufficient responders, 9 patients were not randomised by investigator decision, 2 were randomised to Standard COBRA-Slim and 55 to COBRA-Slim Bio-induction. The results of the CareRA2020 trial showed that more than half of the CareRA2020 participants achieved remission with COBRA-Slim induction therapy. The CareRA2020 trial was conducted from August 11, 2023 by guest. Protected by copyright.http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2023-eular.523 on 30 May 2023. Downloaded from